• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Wednesday's Intraday Session

    10/25/23 1:31:14 PM ET
    $BTAI
    $CBIO
    $CBUS
    $DRIO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BTAI alert in real time by email

    Gainers

    • Werewolf Therapeutics (NASDAQ:HOWL) shares rose 30.0% to $2.34 during Wednesday's regular session. As of 13:30 EST, this security is trading at a volume of 1.4 million shares, making up 4222.8% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $83.4 million.
    • Reshape Lifesciences (NASDAQ:RSLS) stock moved upwards by 24.06% to $0.26. Trading volume for this security as of 13:30 EST is 46.7 million, which is 2583.2% of its average full-day volume over the last 100 days. The company's market cap stands at $1.3 million.
    • BioXcel Therapeutics (NASDAQ:BTAI) shares rose 17.94% to $2.76. The current volume of 63.0 million shares is 4607.2% of BioXcel Therapeutics's average full-day volume over the last 100 days (last updated at 13:30 EST). The market value of their outstanding shares is at $80.7 million.
    • iSpecimen (NASDAQ:ISPC) stock moved upwards by 16.66% to $0.56. The company's market cap stands at $5.0 million.
    • Titan Pharma (NASDAQ:TTNP) shares increased by 16.5% to $0.43. Trading volume for this security as of 13:30 EST is 170.4K, which is 181.3% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $6.4 million.
    • Catalyst Biosciences (NASDAQ:CBIO) stock moved upwards by 15.95% to $0.5. Trading volume for Catalyst Biosciences's stock is 303.2K as of 13:30 EST. This is 77.1% of its average full-day volume over the last 100 days. The company's market cap stands at $18.9 million.

    Losers

    • Sonnet BioTherapeutics (NASDAQ:SONN) stock declined by 29.6% to $1.27 during Wednesday's regular session. As of 13:30 EST, Sonnet BioTherapeutics's stock is trading at a volume of 617.5K, which is 874.8% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $2.2 million.
    • Motus GI Hldgs (NASDAQ:MOTS) shares fell 23.65% to $0.51. Trading volume for this security as of 13:30 EST is 413.2K, which is 275.6% of its average full-day volume over the last 100 days. The company's market cap stands at $3.0 million.
    • Cibus (NASDAQ:CBUS) stock declined by 22.94% to $10.65. Cibus's stock is trading at a volume of 312.3K shares as of 13:30 EST. This is 528.3% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $177.2 million.
    • DarioHealth (NASDAQ:DRIO) stock decreased by 22.34% to $1.6. The current volume of 231.4K shares is 204.6% of DarioHealth's average full-day volume over the last 100 days (last updated at 13:30 EST). The market value of their outstanding shares is at $43.5 million.
    • Heart Test Laboratories (NASDAQ:HSCS) shares fell 20.63% to $0.24. Trading volume for Heart Test Laboratories's stock is 152.4K as of 13:30 EST. This is 153.1% of its average full-day volume over the last 100 days. The company's market cap stands at $2.6 million.
    • Tharimmune (NASDAQ:THAR) stock decreased by 20.01% to $0.2. Trading volume for Tharimmune's stock is 1.3 million as of 13:30 EST. This is 55.6% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $3.5 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $BTAI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BTAI
    $CBIO
    $CBUS
    $DRIO

    CompanyDatePrice TargetRatingAnalyst
    BioXcel Therapeutics Inc.
    $BTAI
    3/17/2026$17.00Buy
    Rodman & Renshaw
    Crescent Biopharma Inc.
    $CBIO
    1/28/2026$35.00Overweight
    Piper Sandler
    Crescent Biopharma Inc.
    $CBIO
    1/21/2026$35.00Buy
    Guggenheim
    Werewolf Therapeutics Inc.
    $HOWL
    12/19/2025$1.00Outperform → Neutral
    Wedbush
    Crescent Biopharma Inc.
    $CBIO
    8/25/2025$26.00Buy
    Jefferies
    Crescent Biopharma Inc.
    $CBIO
    8/11/2025$25.00Buy
    H.C. Wainwright
    Crescent Biopharma Inc.
    $CBIO
    7/14/2025$27.00Outperform
    Wedbush
    Crescent Biopharma Inc.
    $CBIO
    6/25/2025$28.00Buy
    Stifel
    More analyst ratings

    $BTAI
    $CBIO
    $CBUS
    $DRIO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    BioXcel Therapeutics Announces Food & Drug Administration Acceptance of Supplemental New Drug Application for Use of IGALMI® in the At-Home Setting

    PDUFA target action date of November 14, 2026 Potential first FDA-approved treatment option for the acute treatment of agitation associated with bipolar disorders or schizophrenia in the at-home (outpatient) setting NEW HAVEN, Conn., April 01, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (NASDAQ:BTAI), a biopharmaceutical company built on artificial intelligence ("AI") to develop transformative medicines in neuroscience, today announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental New Drug Application (sNDA) for approval of IGALMI® for at-home use in the acute treatment of agitation associated with bipolar disorders or schizophrenia. The FDA has a

    4/1/26 7:00:00 AM ET
    $BTAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Crescent Biopharma Announces Grants of Inducement Awards

    WALTHAM, Mass., March 27, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. ("Crescent" or the "Company") (NASDAQ:CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that the independent Compensation Committee of its Board of Directors approved the grant of options to purchase an aggregate of 35,325 shares of the Company's ordinary shares to three non-executive employees as equity inducement awards under the Crescent Biopharma, Inc. 2025 Employment Inducement Incentive Award Plan, as amended (the "Inducement Plan"). The options were approved on March 26, 2026 and were material to each employee's accept

    3/27/26 4:15:00 PM ET
    $CBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Werewolf Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates

    WATERTOWN, Mass., March 27, 2026 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the "Company" or "Werewolf") (NASDAQ:HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions, today provided a business update and reported financial results for the fourth quarter and year ended December 31, 2025. "We have initiated a process to explore a range of alternatives available to the Company to maximize stockholder value," said Daniel J. Hicklin, Ph.D., President and Chief Executive Officer of Werewolf. "Such measures may includ

    3/27/26 7:00:00 AM ET
    $HOWL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BTAI
    $CBIO
    $CBUS
    $DRIO
    SEC Filings

    View All

    HeartSciences Inc. filed SEC Form 8-K: Leadership Update

    8-K - HeartSciences Inc. (0001468492) (Filer)

    4/3/26 5:15:10 PM ET
    $HSCS
    Industrial Specialties
    Health Care

    SEC Form 10-K filed by iSpecimen Inc.

    10-K - iSpecimen Inc. (0001558569) (Filer)

    4/1/26 5:00:21 PM ET
    $ISPC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    BioXcel Therapeutics Inc. filed SEC Form 8-K: Other Events

    8-K - BioXcel Therapeutics, Inc. (0001720893) (Filer)

    4/1/26 6:58:25 AM ET
    $BTAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BTAI
    $CBIO
    $CBUS
    $DRIO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Rodman & Renshaw initiated coverage on BioXcel Therapeutics with a new price target

    Rodman & Renshaw initiated coverage of BioXcel Therapeutics with a rating of Buy and set a new price target of $17.00

    3/17/26 8:16:49 AM ET
    $BTAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Piper Sandler initiated coverage on Crescent Biopharma with a new price target

    Piper Sandler initiated coverage of Crescent Biopharma with a rating of Overweight and set a new price target of $35.00

    1/28/26 7:10:21 AM ET
    $CBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Guggenheim initiated coverage on Crescent Biopharma with a new price target

    Guggenheim initiated coverage of Crescent Biopharma with a rating of Buy and set a new price target of $35.00

    1/21/26 8:54:45 AM ET
    $CBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BTAI
    $CBIO
    $CBUS
    $DRIO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Sauer Noel

    4 - Cibus, Inc. (0001705843) (Issuer)

    4/1/26 12:03:47 PM ET
    $CBUS
    Agricultural Chemicals
    Industrials

    SEC Form 4 filed by Stokes Jason

    4 - Cibus, Inc. (0001705843) (Issuer)

    4/1/26 12:00:59 PM ET
    $CBUS
    Agricultural Chemicals
    Industrials

    SEC Form 4 filed by Broos Carlo

    4 - Cibus, Inc. (0001705843) (Issuer)

    4/1/26 11:57:01 AM ET
    $CBUS
    Agricultural Chemicals
    Industrials

    $BTAI
    $CBIO
    $CBUS
    $DRIO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Fairmount Funds Management Llc bought $18,237,600 worth of Ordinary Shares (1,360,000 units at $13.41) (SEC Form 4)

    4 - CRESCENT BIOPHARMA, INC. (0001253689) (Issuer)

    12/8/25 4:30:15 PM ET
    $CBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President and CCO Nelson Steven Charles bought $21,200 worth of shares (40,000 units at $0.53), increasing direct ownership by 73% to 95,000 units (SEC Form 4)

    4 - DarioHealth Corp. (0001533998) (Issuer)

    8/27/25 4:30:59 PM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    Executive Chairman Gravitas Capital Lp bought $500,000 worth of shares (337,838 units at $1.48), increasing direct ownership by 86% to 732,424 units (SEC Form 4)

    4 - Tharimmune, Inc. (0001861657) (Issuer)

    6/23/25 9:29:23 PM ET
    $THAR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BTAI
    $CBIO
    $CBUS
    $DRIO
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for IGALMI issued to BIOXCEL THERAPEUTICS, INC.

    Submission status for BIOXCEL THERAPEUTICS, INC.'s drug IGALMI (ORIG-1) with active ingredient DEXMEDETOMIDINE has changed to 'Approval' on 04/05/2022. Application Category: NDA, Application Number: 215390, Application Classification: Type 3 - New Dosage Form

    4/6/22 2:18:32 PM ET
    $BTAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BTAI
    $CBIO
    $CBUS
    $DRIO
    Leadership Updates

    Live Leadership Updates

    View All

    Tharimmune, Inc. Appoints Mark Wendland Chairman of the Board and Names Angela Radkowski Chief Operating Officer

    Leadership Expansion Supports Execution of Canton Network Infrastructure Strategy Former DRW and Citadel Leader Joins as COO to Drive Institutional Platform Expansion NEW YORK, Feb. 6, 2026 /PRNewswire/ -- Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), the first publicly traded company to leverage Canton Coin ("CC") to support the Canton Network's ability to digitize traditional financial markets, today announced that its Board of Directors (the "Board") has elected Mark Wendland, Chief Executive Officer, as Chairman of the Board and approved the appointment of Angela Radkowski as Chief Operating Officer, effective February 5, 2026. Mr. Wendland succeeds Vincent LoPriore, wh

    2/6/26 8:15:00 AM ET
    $THAR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tharimmune Elects Jill Sommers and William Wiley to Board of Directors

    New Directors Strengthen Governance as Company Advances Canton Network Infrastructure Former CFTC Commissioner Jill Sommers Brings Decades of Regulatory and Public Policy Experience DRW Chief of Staff William Wiley, CFA, Adds Extensive Leadership Experience Across Capital Markets and Global Operations NEW YORK, Feb. 2, 2026 /PRNewswire/ -- Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), the first publicly traded company to leverage Canton Coin ("CC") to support the Canton Network's ability to digitize traditional financial markets, today announced that its Board of Directors (the "Board") has elected Jill Sommers and William Wiley, CFA, to the Board, effective February 1, 20

    2/2/26 8:15:00 AM ET
    $THAR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BioXcel Therapeutics Expands Leadership Team to Prepare for Launch of IGALMI® in the At-Home Setting

    Mark Pavao to Join BioXcel Therapeutics as Interim Chief Commercial Officer Mr. Pavao Brings Deep Experience in Neuroscience Sales and Marketing to Support Potential Launch of IGALMI® in At-Home Setting as Early as Year-End 2026 BioXcel Therapeutics on Track to Submit a sNDA for IGALMI® this Month NEW HAVEN, Conn., Jan. 12, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (NASDAQ:BTAI), a biopharmaceutical company built on artificial intelligence ("AI") to develop transformative medicines in neuroscience, today announced the advancement of its commercial planning for IGALMI® in the at-home setting. As part of this, Mark Pavao, a commercial planning and launch advisor with more than 3

    1/12/26 7:00:00 AM ET
    $BTAI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BTAI
    $CBIO
    $CBUS
    $DRIO
    Financials

    Live finance-specific insights

    View All

    DarioHealth Reports Fourth Quarter and Full Year 2025 Financial and Operating Results

    Fourth quarter 2025 revenues grew sequentially to $5.2 million as compared to $5.0 million in the third quarter of 20252025 full-year revenue was $22.4 million, compared to $27.0 million in 2024, due entirely to a scope change and nonrenewal from a single legacy client that came through the Twill, Inc. ("Twill") acquisition — unrelated to demand — partially offset by organic revenue growth The 2025 sales season — Dario's strongest on record — generated $12.9 million in contracted and late stage, annual recurring revenue ("ARR")  set to contribute revenue in 2026 and 2027 and position the Company for a high-growth trajectoryGAAP gross margins increased to 57% in 2025 from 49% in 2024 and Non-

    3/19/26 6:30:00 AM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    DarioHealth to Report Fourth Quarter and Full Year 2025 Results on Thursday, March 19, 2026

    Company to host conference call and webcast at 8:30 a.m. Eastern TimeNEW YORK, March 11, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today that it will release its financial results for the 4th quarter ended December 31st, 2025 and will host a conference call and webcast at 8:30 a.m. Eastern Time, on Thursday, March 19th, 2026, before the market opens. Erez Raphael, Chief Executive Officer, Steven Nelson, President and Chief Commercial Officer, and Chen Franco-Yehuda, Chief Financial Officer, will host the call.Conference Call DetailsDate: Thursday, March19th, 2026, 8:30 a.m. Eastern TimeDial-in Numb

    3/11/26 8:30:00 AM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    Cibus to Report Fourth Quarter 2025 Financial Results on March 17, 2026 After the Market Close and Host Conference Call

    SAN DIEGO, March 03, 2026 (GLOBE NEWSWIRE) -- Cibus, Inc. (NASDAQ:CBUS), a leading agricultural technology company that develops and licenses plant traits to seed companies, today announced that the company will report fourth quarter 2025 financial results on Tuesday, March 17, 2026. Cibus' management team will host a conference call and audio webcast at 4:30 p.m. ET on that day to discuss the financial results and other company updates. Title: Cibus, Inc. Fourth Quarter 2025 Results Conference Call Event Date: Tuesday, March 17, 2026Time: 4:30 p.m. ETParticipant Numbers: +1-800-343-5172 (U.S.), +1-203-518-9856 (International)The conference ID "CIBUS" or 24287 will be required for entryEv

    3/3/26 4:05:00 PM ET
    $CBUS
    Agricultural Chemicals
    Industrials

    $BTAI
    $CBIO
    $CBUS
    $DRIO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by DarioHealth Corp.

    SC 13G - DarioHealth Corp. (0001533998) (Subject)

    12/13/24 4:05:12 PM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Motus GI Holdings Inc.

    SC 13G/A - Motus GI Holdings, Inc. (0001686850) (Subject)

    11/14/24 4:22:34 PM ET
    $MOTS
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Werewolf Therapeutics Inc.

    SC 13G/A - Werewolf Therapeutics, Inc. (0001785530) (Subject)

    11/14/24 4:04:06 PM ET
    $HOWL
    Biotechnology: Pharmaceutical Preparations
    Health Care